Kodak Introduces Four New Pharmaceutical Products

Expansion into laboratory reagents marks milestone for company's long-term plan.

Jan. 27, 2026 at 10:47am

Got story updates? Submit your updates here. ›

Kodak, the iconic photography company, is expanding its pharmaceutical portfolio with the introduction of four new products. These new offerings are variations of "phosphate buffered saline" and "water for injection", which are essential ingredients for laboratory research. The company is working to offer more pharmaceuticals as part of its long-term strategy.

Why it matters

Kodak's move into the pharmaceutical space represents a diversification of the company's business beyond its traditional photography roots. The new laboratory reagent products could provide a steady revenue stream and position Kodak as a supplier of critical materials for scientific research.

The details

The four new products are unregulated "key starting materials" that will complement Kodak's existing pharmaceutical business. The company says the expansion into high-quality, reliable Class 1 regulated laboratory reagents is a milestone in its long-term plan to grow its pharmaceutical offerings.

  • Kodak announced the new products on January 27, 2026.

The players

Kodak

An iconic American company known for its photography products that is now expanding into the pharmaceutical industry.

Jim Continenza

Kodak's Executive Chairman and CEO, who announced the company's expansion into new pharmaceutical products.

Got photos? Submit your photos here. ›

What they’re saying

“The expansion of Kodak's existing unregulated key starting materials business to include high-quality, reliable Class 1 regulated laboratory reagents is a milestone in our long-term plan.”

— Jim Continenza, Executive Chairman and CEO

What’s next

Kodak plans to continue expanding its pharmaceutical offerings in the future as part of its long-term strategy.

The takeaway

Kodak's move into the pharmaceutical industry, starting with essential laboratory reagents, represents a significant diversification of the company's business model beyond its traditional photography roots. This expansion could provide new revenue streams and position Kodak as a supplier of critical materials for scientific research.